BioSpace News Archive

Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that data from the previously announce Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV related cancers.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Immunotherapy is a cancer treatment that improves the immune system’s ability to fight cancer.

The biobanking market has been estimated to experience novel growth opportunities in the forthcoming years.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Rapid influenza diagnostic tests refer to the process of evaluation of antigen detection, which identifies influenza viral antigens with a very short span of time, within 10 to 15 minutes, with high accuracy.

Olanzapine is an antipsychotic drug used for short-term treatment of minor maniac cases of bipolar disorder or Schizophrenia.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Mucosal atomization devices are primarily used to deliver drugs through nasal mucosa for treating chronic diseases such as allergic rhinitis and sinusitis.

The global market for microbiology testing is estimated to expand at a promising pace in the next few years owing to the massive rise in the awareness level among patients about the variety of rampant chronic diseases, respiratory infections, and inflammatory conditions.

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will participate in a fireside chat at the H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference taking place virtually on July 20, 2022.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today launched two human monkeypox virus synthetic DNA controls .